Nav: Home

MCG receives second-time designation from National Cancer Institute

December 20, 2007

The Medical College of Georgia has again been designated by the National Cancer Institute as a Minority-Based Community Clinical Oncology Program.

The renewal, which comes with a five-year $2.3 million grant, provides more access to the latest cancer treatment and prevention strategies for all cancer patients, particularly minorities, says Dr. Anand Jillella, chief of the MCG section of Hematology/Oncology and principal investigator on the grant.

"The real advantage of the grant is that it is minority-based, which is really relevant here because we have such a significant number of minority patients," says Dr. Kapil N. Bhalla, director of the Medical College of Georgia Cancer Center. "The National Cancer Institute recognizes the need to extend studies and clinical trials to those populations and this grant enables us to help advance that initiative by supporting the work done by cancer researchers and clinicians here. This type of work is integral to the overall mission of the Cancer Center - to facilitate and inspire cancer research. It is the perfect marriage of our clinical and research components."

MCG, eligible because more than 40 percent of its newly-diagnosed patients and 40 percent of patients enrolled in clinical trials are minorities, first received the designation in 2004.

The Veterans Affairs Medical Center in Augusta, Aiken Regional Medical Center in Aiken, S.C., and Athens Regional Medical Center in Athens, Ga., are collaborators on the grant.

Dr. Daron G. Ferris, family medicine physician and director of the Gynecologic Cancer Prevention Center at MCG, and Dr. Roger A. Vega, chief of the MCG Section of Pediatric Hematology/Oncology are co-principal investigators.

"This designation allows us to continue to broaden the scope of clinical trials and prevention programs by providing support for the infrastructure those initiatives require," Dr. Jillella says.

Unlike the typical grant, program funding supports the infrastructure for dozens of clinical studies instead of just one, says Dr. Jillella.

"Before this grant, providing trials was difficult because we could not support the personnel needed for that," he says. "Because of the CCOP, we can hire the personnel we need, including research nurses, study coordinators and administrative assistants who are all an important part of clinical research activity."

The grant also allows for collaborative work between adult, preventive and pediatric cancer researchers and clinicians.

"One particular way that we have and will continue to benefit from this grant is in the increasing collaboration between adult and pediatric oncology," says Dr. Vega. "Having this grant as the common denominator allows us to share. There is a lot that both sides can learn from each other."

For example, he says, young adults who are diagnosed with cancer often fall in the middle between adult and pediatric oncology. While pediatricians treat patients until age 21, many pediatric trials do not apply to those older patients.

"Because of the CCOP cooperation, we can extend adult trials to our pediatric patients that wouldn't have been available before," he says.

The grant also provides money for studies on preventing cancer and studies that can help improve the quality of life for patients already undergoing treatments.

"There's a lot of research being done on potential treatments, but there's only a drop in the bucket of studies that focus on the patient with cancer," says Dr. Ferris. "When people have cancer, clearly, one of the major goals is to cure it. But we also realize that during that process, some bad things can happen. That's where we come in. We need to find ways to minimize suffering and make the treatment period more tolerable for the patient. Are there better medications" Alternative treatments for side effects of drugs"

These types of studies also help patients take an active part in their cancer, which gives them hope for themselves, their friends and their families."
-end-


Medical College of Georgia at Augusta University

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...